2024
Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study
Thanarajasingam G, Kluetz P, Bhatnagar V, Brown A, Cathcart-Rake E, Diamond M, Faust L, Fiero M, Huntington S, Jeffery M, Jones L, Noble B, Paludo J, Powers B, Ross J, Ritchie J, Ruddy K, Schellhorn S, Tarver M, Dueck A, Gross C. Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study. BMJ Open 2024, 14: e074030. PMID: 38199641, PMCID: PMC10806877, DOI: 10.1136/bmjopen-2023-074030.Peer-Reviewed Original ResearchMeSH KeywordsAmbulatory Care FacilitiesBreast NeoplasmsFabaceaeFemaleHumansLymphomaMedical OncologyProspective StudiesUnited StatesConceptsPhysical function assessmentPhysical functionFunctional assessmentEvaluation of physical functionElectronic health record dataEvaluate physical functionHealth record dataSpanish-speaking patientsDigital health technologiesBreast cancerProspective cohort studyClinician-reported outcomesCancer clinical trialsClinical decision-makingStudy questionnairePatient-centred evaluationHealth technologiesMeasure symptomsOncology practiceCohort studyRecord dataPatient's impressionMayo ClinicEnglish-speakingWearable sensors
2019
Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.
Huntington SF, Davidoff AJ, Gross CP. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs. Journal Of Clinical Oncology 2019, 38: 351-358. PMID: 31804866, DOI: 10.1200/jco.19.01573.Commentaries, Editorials and Letters
2012
Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy
Huntington SF, Talbott MS, Greer JP, Morgan DS, Reddy N. Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. Leukemia & Lymphoma 2012, 53: 1461-1468. PMID: 22260160, PMCID: PMC7845767, DOI: 10.3109/10428194.2012.658793.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsComorbidityCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleGeriatricsHumansLymphoma, Large B-Cell, DiffuseMaleMedical OncologyMiddle AgedPrednisoneRemission InductionRetrospective StudiesRituximabTreatment OutcomeVincristineConceptsNon-Hodgkin lymphomaLarge cell lymphomaCell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaChemotherapy dose reductionsTreatment-related toxicityR-CHOP treatmentSingle-institution studyB-cell lymphomaCurative intentRelative chemotherapyComplete remissionPrimary therapyElderly patientsSupportive careTreatment toxicityAged patientsPatient populationTreatment outcomesRetrospective analysisDose reductionElderly populationPatientsLymphoma